AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

The stock's fall snapped a two-day winning streak.

Astrocytes are star-shaped glial cells in the central nervous system that support neuronal function, maintain the blood-brain ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $176.19 which represents a slight increase of $0.02 or 0.01% from the prior close of $176.17. The stock opened at $176 and touched a low ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...

Quantbot Technologies LP bought a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 3rd quarter, ...